利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

56 条记录 (耗时 0.018 秒)

    ANALYSIS OF ANTIBODIES
    32.
    发明公开
    ANALYSIS OF ANTIBODIES 审中-公开
    ANALYZE VONANTIKÖRPERN

    公开(公告)号：EP3084439A1

    公开(公告)日：2016-10-26

    申请号：EP14824416.3

    申请日：2014-12-16

    申请人： Phadia AB

    发明人： MOVÉRARE, Robert ,  ERIKSSON, Camilla ,  VENEMALM, Lennart

    IPC分类号： G01N33/543 ,  G01N33/68

    CPC分类号： G01N33/6854 ,  G01N33/54353 ,  G01N33/94

    摘要： The present invention relates to a method which may be used for the analysis of endogenously formed antibodies such as anti-drug antibodies (ADAs) or rheumatoid factor (RF) in a solution, which method comprises (a) contacting the solution with a solid phase to which e.g. IgG molecule(s) have been attached; (b) allowing the ADAs or RF to bind specifically to the attached molecule(s); (c) adding a labeled isotype-specific reagent capable of binding ADAs or RF; (d) removing any excess of reagent; and (f) detecting the label bound or unbound to determine directly or indirectly the presence or concentration of ADAs in the solution. The molecule(s) have been attached to the solid phase via a linker, which may be an organic molecule, an amino acid, a peptide, a protein a molecule of protein origin, a monosaccharide, an oligosaccharide or a polysaccharide. The method according to the invention may be used e.g. as an immunoassay for making clinical decisions in patient care, as well as in the development of new drugs.

    摘要翻译： 本发明涉及一种可用于分析溶液中内源性形成的抗体如抗药物抗体（ADAs）或类风湿因子（RF）的方法，该方法包括（a）使溶液与固相 例如 IgG分子已经附着; （b）允许ADAs或RF特异性结合附着的分子; （c）加入能够结合ADAs或RF的标记的同种型特异性试剂; （d）除去过量的试剂; 和（f）检测结合或未结合的标记直接或间接确定溶液中ADAs的存在或浓度。 分子已经通过接头连接到固相，接头可以是有机分子，氨基酸，肽，蛋白质的蛋白质分子，单糖，寡糖或多糖。 根据本发明的方法可以例如使用。 作为在患者护理中进行临床决定以及开发新药的免疫测定。

    METHOD FOR DECISION SUPPORT IN ALLERGY DIAGNOSIS
    35.
    发明公开
    METHOD FOR DECISION SUPPORT IN ALLERGY DIAGNOSIS 审中-公开
    程序对决策支持过敏诊断

    公开(公告)号：EP2577308A4

    公开(公告)日：2013-12-04

    申请号：EP11790083

    申请日：2011-05-27

    申请人： PHADIA AB

    发明人： ANDERSSON KARL ,  MATSSON PER

    IPC分类号： G01N33/53 ,  G01N33/68 ,  G06F19/00

    CPC分类号： G06F19/34 ,  G01N33/68 ,  G01N2800/24

    摘要： A method of providing a clinical decision support in allergy diagnosis comprises the steps of: a) providing a body fluid sample from a patient, b) selecting a plurality of allergens to be tested for in the sample, c) determining for each allergen the concentration in the sample of at least one immunoglobulin directed against the allergen, d) transforming each determined immunoglobulin concentration to a clinical effect value on a normalized scale common to allergens in general, e) assigning to each allergen tested for, based on known cross-reactivity information for the allergen, an allergen specificity value, representing the degree of cross-reactivity for the allergen, and f) presenting determined clinical effect and allergen specificity values for each allergen, or a group or groups of the allergens. A computer-implemented method, a computer program product, and a patient information carrier device containing a diagnosis result are also disclosed.

    NOVEL ALLERGEN
    36.
    发明公开
    NOVEL ALLERGEN 有权
    新的过敏原

    公开(公告)号：EP2560990A1

    公开(公告)日：2013-02-27

    申请号：EP11772331.2

    申请日：2011-04-26

    申请人： Phadia AB

    发明人： Mattsson, Lars ,  Lidholm, Jonas ,  Lundgren, Thomas

    IPC分类号： C07K14/47 ,  A61K39/35 ,  A61P37/08 ,  G01N33/68

    CPC分类号： A61K39/35 ,  A61K2039/577 ,  C07K14/47 ,  G01N33/6854 ,  G01N2800/24

    摘要： An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.

    摘要翻译： 公开了一种分离的马过敏原，它是非还原条件下分子量为15kDa的分泌蛋白，包含分子量约为5kDa的第一肽链和分子量约为10kDa的第二肽链， 一起，以及与其共享抗原表位的变体和片段。 还公开了使用过敏原进行诊断和治疗，以及含有过敏原的诊断试剂盒和药物组合物。